GlassScriptPhysician profile
David Clayton Craig
NPI 1407518442
$986.25
in general payments reported to CMS, 2019-2025
21 companies · $967 in 2025
The $967 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.54 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $966.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $201.98 | 2025 | |
| Vanda Pharmaceuticals INC. | $92.05 | 2025 | Ponvory |
| Pfizer INC. | $74.88 | 2025 | |
| Ucb, INC. | $68.21 | 2025 | Fintepla, Nayzilam |
| Biogen, INC. | $65.41 | 2025 | Skyclarys, Spinraza |
| Csl Behring | $45.63 | 2025 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $44.20 | 2025 | Wainua |
| Teva Pharmaceuticals USA, INC. | $43.12 | 2025 | Austedo Xr |
| Sk Life Science, INC. | $42.99 | 2025 | |
| Genentech USA, INC. | $42.18 | 2025 | Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $36.72 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $35.47 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $30.39 | 2025 | Hyqvia |
| Amgen INC. | $28.18 | 2025 | Uplizna |
| Genzyme Corporation | $24.04 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tg Therapeutics, INC. | $23.77 | 2025 | |
| Lundbeck LLC | $22.39 | 2025 | Vyepti |
| Ipsen Biopharmaceuticals, INC | $19.54 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.20 | 2025 | Crexont |
| Jazz Pharmaceuticals INC. | $18.28 | 2025 | |
| Aucta Pharmaceuticals, INC. | $7.62 | 2025 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Craig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.